The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge.
about
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV TransmissionApproved Antiviral Drugs over the Past 50 YearsProfile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to dateApplying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, GeorgiaA long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions.Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.Formulation and pharmacology of long-acting cabotegravir.Long-Acting Antiretrovirals: Where Are We now?Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences.Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.Long-Acting HIV Treatment and Prevention: Closer to the Threshold.Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy.Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution.Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy.Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.Investigational HIV integrase inhibitors in phase I and phase II clinical trials.Pharmacokinetic and Chemical Synthesis Optimization of a Potent d-Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery.Ultra-long-acting removable drug delivery system for HIV treatment and prevention
P2860
Q27318354-B5273FE1-925D-4D82-A142-75B06FD2C96BQ27755387-81120A3E-E24F-4ADD-80D4-86D259AE2D41Q28079025-60FE59A7-9062-495A-92E5-365961AB5716Q28088473-E55D35BD-896D-4971-AC3B-685CA8727DD5Q35667426-38DA8F64-F2F1-4635-8346-57DFE6CAB6F4Q35817533-FBE4E508-456A-46DB-B28C-9C5645D3CF90Q36816564-8430B402-A525-42DF-8641-D459D7F160ADQ36901505-AB482B41-B192-4BBF-873C-EBDAB343CAD0Q36934918-7DECFBBC-8712-4D6D-8C66-07238B155DABQ38518434-5D51E5A2-F8AA-4300-AD60-EB23142EB3B7Q38902077-599C6F88-9E76-4786-AA6E-C2E3B6A978F3Q38936872-543A8B79-8817-4998-8FC2-37C9C8C8DE3FQ40429647-ADF014FE-1E2A-4A79-81EE-F4A741418A36Q42334096-9584464A-BBCB-45BA-B6C1-B81E77B3E40CQ45326424-D5F77E5F-C0FD-4887-B72A-7BD09937A519Q47095093-8235676A-B52D-44E6-86AA-3CE656592F7FQ47377243-C6DDC469-A09D-4DB4-8DB2-8D5D40924345Q47603651-C418BFEB-9123-4B3E-8267-D70FB2EDBC56Q47909110-01E94453-58F3-4F76-81A5-C6A989B4BB54Q50046992-35190F70-4C8A-45FF-9E8C-95EB8AF8B2EDQ57295387-869D5CEB-EE36-45D8-BA5A-BE96C9637296
P2860
The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The long-acting integrase inhi ...... d intravaginal SHIV challenge.
@en
type
label
The long-acting integrase inhi ...... d intravaginal SHIV challenge.
@en
prefLabel
The long-acting integrase inhi ...... d intravaginal SHIV challenge.
@en
P2093
P2860
P1476
The long-acting integrase inhi ...... d intravaginal SHIV challenge.
@en
P2093
J Gerardo García-Lerma
James Mitchell
Jessica Radzio
Leecresia Jenkins
William Spreen
Yun Lan Yueh
P2860
P304
P356
10.1126/SCITRANSLMED.3010297
P407
P577
2015-01-01T00:00:00Z